AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05627414
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: 40\~60mg / m2, bid, d1-14, repeated every 3 weeks.
Trial: NCT05479214
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1gm tablet with the 2 main meals
Trial: NCT05479214
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous insulin daily administration
Trial: NCT04677959
Drug: Fluticasone propionate/salmeterol (FS)
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: FS administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard
Trial: NCT04677959
Drug: Albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard
Trial: NCT06022744
Drug: LX109
RxNorm normalized name: Lixisenatide
DrugBank: Lixisenatide (DB09265)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: LX109 gene injection Specification: 0.2ml/bottle, 1.4×1012VG/ml Administration route: intravitreal injection, injection volume 0.05ml/eye
Trial: NCT05171348
Drug: CM326
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: a humanized monoclonal antibody
Trial: NCT05200663
Drug: Tab Tamoxifen 10 mg
RxNorm normalized name: tamoxifen Oral Tablet
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet tamoxifen 10mg twice a day for 6 months.
Trial: NCT05200663
Drug: Tab Tamoxifen 10mg,Cap vitamin E 400mg
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tab tamoxifen 10 mg is given twice a day and cap vit E 400mg is given once a day for 6 months
Trial: NCT06474949
Drug: Bupivacaine injection
RxNorm normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection at end of Open Reduction Internal Fixation
Trial: NCT05646706
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment was continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Trial: NCT05646706
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Trial: NCT05664958
Drug: bupivacaine liposome injectable suspension
RxNorm normalized name: bupivacaine liposome Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 133 mg liposomal bupivacaine per side.
Trial: NCT05664958
Drug: bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 ml bupivacaine 0.25% per side.
Trial: NCT06119490
Drug: Abrocitinib
RxNorm normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solu-Medrol® 1 mg/kg body weight intravenous infusion per day in combination with Arocitinib tablets 200 mg per day for 2 weeks
Trial: NCT06119490
Drug: Tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Solu-Medrol® 1 mg/kg body weight intravenous infusion per day in combination with Tofacitinib tablets 10 mg per day for 2 weeks
Trial: NCT04137120
Drug: Aflibercept (BAY86-5321, Eylea)
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injection of aflibercept as scheduled by treating physician
Trial: NCT06510361
Drug: Epcoritamab
RxNorm normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humanized IgG1 bispecific antibody, 5 or 60 mL vial, via subcutaneous (under the skin) injection per protocol.
Trial: NCT06385730
Drug: neoadjuvant anti-PD-1 with LDRT
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy: low-dose radiotherapy (LDRT), gross target volume (GTV), DT: 1Gy (day1), 1Gy (day2), every 3 weeks, 2 cycles.~PD-1 inhibitor (toripalimab) 240mg, day 3，every 3 weeks, 2 cycles. Postoperative adjuvant treatment: according to the recommendations of the guidelines and the investigators
Trial: NCT04808648
Drug: SH-1028
RxNorm normalized name: Glutathione-SH
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, oral, 200 mg once daily for day 1 and day 12
Trial: NCT04808648
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: capsule, oral, 200 mg twice daily for day 8 to day 14
Trial: NCT04808648
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: capsule, oral, 600 mg once daily for day 8 to day 16
Trial: NCT06293820
Drug: TL-925
RxNorm normalized name: Thallous chloride Tl 201
DrugBank: Thallous chloride Tl-201 (DB16624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TL-925 is an eye drop.
Trial: NCT05572723
Drug: dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Studies show that dexmedetomidine is superior to currently commonly used remifentanil in terms of intraoperative blood pressure control and postoperative pain.~Dexmedetomidine, an alpha-2-adrenoceptor agonist, has sympatholytic, sedative, anesthetic, analgesic, and vasoconstrictor effects. It lowers blood pressure by decreasing plasma norepinephrine and epinephrine levels, thereby reducing intraoperative bleeding. Dexmedetomidine is defined as an analgesic that is now widely used to induce and maintain anesthesia and to control postoperative pain, and is defined as an analgesic that does not cause respiratory depression and neurocognitive impairment. Many studies have shown that the use of perioperative dexmedetomidine reduces the stress response to anesthetic induction and surgery and provides hemodynamic stability.
Trial: NCT05137184
Drug: Methoxyflurane
RxNorm normalized name: Methoxyflurane
DrugBank: Methoxyflurane (DB01028)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhalation of Methoxyflurane
Trial: NCT05137184
Drug: Morphine hydrochloride
RxNorm normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Morphine
Trial: NCT04848558
Drug: Nipocalimab
RxNorm normalized name: Nipocalimab
DrugBank: Nipocalimab (DB16257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IV infusion or SC injection of nipocalimab.
Trial: NCT00360763
Drug: candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04882150
Drug: BMS-986196
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05855577
Drug: Terazosin
RxNorm normalized name: Terazosin
DrugBank: Terazosin (DB01162)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment of Terazosine vs placebo and Lisosan-G vs placebo in cross-over double-blind, double-dummy
Trial: NCT00293891
Drug: Tacrolimus Cream
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03509545
Drug: CHF Patients: Furosemide 40 mg
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stable CHF patients taking twice-daily 40 mg Furosemide
Trial: NCT05980156
Drug: Dihydroartemisinin-Piperaquine
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will be with DP (females less than 10 years old and all males) or chloroquine alone (females 10 years old or older).
Trial: NCT05980156
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment of females 10 years old and older in Arm 1 and treatment of all participants in Arm 2.
Trial: NCT05980156
Drug: Sulfadoxine pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment will be with SP and chloroquine (females less than 10 years old and all males) or chloroquine alone (females 10 years old or older).
Trial: NCT00000697
Drug: Foscarnet sodium
RxNorm normalized name: Foscarnet Sodium
DrugBank: Foscarnet (DB00529)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05192356
Drug: CKD-348(3)
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT04891744
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.
Trial: NCT04891744
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100mg/d, Po. on day1-28
Trial: NCT04891744
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg/d Po. on day 1, 2,8,9,15,16,22,23
Trial: NCT03402789
Drug: Docosahexaenoic Acid
RxNorm normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docosahexaenoic acid 1,200mg daily plus 2 hours of eye patching daily
Trial: NCT04558866
Drug: Testosterone Cypionate
RxNorm normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One administration every 63 cycles until progression or unacceptable toxicity or completion of treatment phase (54 weeks; 6 cycles), whichever comes first.
Trial: NCT04558866
Drug: Darolutamide
RxNorm normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: During 4 weeks, from day 29 to day 56 of each 63-day cycle (+- 3 days) until progression or unacceptable toxicity or completion of treatment phase (54 weeks; 6 cycles), whichever comes first.
Trial: NCT00000742
Drug: Atevirdine mesylate
RxNorm normalized name: mesylate
DrugBank: Atevirdine (DB12264)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000742
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000742
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05236634
Drug: Phosphodiesterase 5 Inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
Trial: NCT04816253
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediately after removal of impacted tooth (hyaluronic acid) placed in extraction socket
Trial: NCT04816253
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednsolone will be injected half an hour preoperatively
Trial: NCT05017480
Drug: CBP-201
RxNorm normalized name: CBPC
DrugBank: Carbenicillin (DB00578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CBP-201 subcutaneous(SC) injection.
Trial: NCT05905120
Drug: Toludivenlafaxine hydrochloride sustained-release tablets
RxNorm normalized name: bupropion
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg/tablet, 2 tablets each time, once a day, for 4 days, orally at 30 min after the start of meals, 200 mL water to take
Trial: NCT06279286
Drug: HS-10506
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HS-10506, tablets (10mg, 20mg, 40mg and 80mg) at night once daily from Day 1 to Day 5 in phase Ib study, and from Day 1 to Day 28 in phase II study.
Trial: NCT05920889
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.5mg subcutaneous injection of the drug before or during EVT, and 7 days after the procedure. i.e. patient will receive a total of 2 injections.
Trial: NCT05502250
Drug: gemcitabine, cisplatin and tislelizumab
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will receive 2 cycles of gemcitabine and cisplatin (GP) + tislelizumab. Each cycle lasts 21 days. Treatment is given through an IV line on day 1 and 8.~After 2 cycles a FDG-PET-CT scan will be performed. Patients who respond well will proceed with 2 additional cycles of GP + tislelizumab . Patients with insufficient response will stop with the study treatment and they will continue treatment according to local practice.~After 4 cycles of GP + tislelizumab another FDG-PET-CT scan will be performed. If this scan shows that the disease is under control (metabolic complete remission) patients will proceed with 13 cycles of tislelizumab consolidation treatment (21 day cycles). Treatment is given on day 1 through an IV line.
Trial: NCT06099379
Drug: ∆9-tetrahydrocannabinol
DrugBank: Cannabinol (DB14737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytocannabinoids from plant inflorescences (CBD and THC dominant) - inhaled
Trial: NCT06407297
Drug: UCMSCs
RxNorm normalized name: HUCMSCs
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral intravenous infusion of umbilical cord mesenchymal stem cells
Trial: NCT05038657
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment will consist of atezolizumab, by IV infusion, at a fixed dose of 1680 mg, every 28 days (day 1 of each cycle, +/- 3 days), for up to one year. Each participant will receive up to 13 doses in total.
Trial: NCT05151588
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75mg/m2 intravenous infusion on day 1 every 3 weeks for 3 cycles as induction therapy
Trial: NCT05151588
Drug: Cis Platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 75mg/m2 intravenous infusion on day 1 every 3 weeks for 3 cycles as induction therapy
Trial: NCT05151588
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 750mg/m2 intravenous infusion from day 1 to day 5 every 3 weeks for 3 cycles as induction therapy
Trial: NCT05151588
Drug: Tazemetostat
RxNorm normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tazemetostat 800mg twice per day orally in continuously for 3 cycles as induction therapy and maintenance therapy
Trial: NCT05096663
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally (PO)
Trial: NCT05096663
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05096663
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05096663
Drug: Nogapendekin Alfa
RxNorm normalized name: Nogapendekin alfa
DrugBank: Nogapendekin alfa (DB18740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given SC
Trial: NCT05096663
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT05913661
Drug: Pemigatinib
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pemigatinib is scheduled to be administered at a dose of 13.5 mg quaque die according to a 2-week dosing and 1-week discontinuation regimen.
Trial: NCT05913661
Drug: PD-1 Inhibitors
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosing regimen is 200 mg IV Q3W
Trial: NCT06246565
Drug: HS-10383
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HS-10383 administered as one 50 mg, 100 mg 200 mg tablet once daily, depending upon randomization.
Trial: NCT06490913
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130mg/m2, ivgtt, d1，q3w，1cycle
Trial: NCT06490913
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: cetuximab 500mg/m2, q2w
Trial: NCT06490913
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85mg/m2, d1,q2w
Trial: NCT06490913
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg/m2，d1,q2w
Trial: NCT06215976
Drug: Metformin Hydrochloride 500 MG
RxNorm normalized name: metformin hydrochloride 500 MG
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 500mg tablets twice daily
Trial: NCT05169515
Drug: SC Mosunetuzumab
RxNorm normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SC mosunetuzumab for 12 cycles (cycle length = 21 days or 28 days for Cycle 1 and 28 days for Cycles 2-12)
Trial: NCT05169515
Drug: IV Glofitamab
RxNorm normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IV glofitamab for 12 cycles (cycle length = 21 days)
Trial: NCT05169515
Drug: Iberdomide
RxNorm normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 1: Participants will receive oral CC-220 from Day 1-21 of Cycle 2-12 (cycle length = 28 days for Cycles 2-12)
Trial: NCT05506007
Drug: DA-5216
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the cross-over \[Part A\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.~* Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8.
Trial: NCT05506007
Drug: DA-5216
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the cross-over \[Part B\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216(Fed) on Day 8.~* Sequence II. Single dose of DA-5216(Fed) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.
Trial: NCT04865653
Drug: Lysergic Acid Diethylamide Base oral drinking solution
RxNorm normalized name: Lysergic acid diethylamide
DrugBank: Lysergic acid diethylamide (DB04829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A moderate dose of 0.1 mg LSD will be administered.
Trial: NCT04865653
Drug: Lysergic Acid Diethylamide Base solid orodispersible film
RxNorm normalized name: Lysergic acid diethylamide
DrugBank: Lysergic acid diethylamide (DB04829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A moderate dose of 0.1 mg LSD will be administered.
Trial: NCT04865653
Drug: Lysergic Acid Diethylamide Tartrate oral drinking solution
RxNorm normalized name: tartrate
DrugBank: Lysergic acid diethylamide (DB04829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).
Trial: NCT04865653
Drug: Lysergic Acid Diethylamide Tartrate intravenous administration
RxNorm normalized name: tartrate
DrugBank: Lysergic acid diethylamide (DB04829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).